PTX4

Across TCGA pan-cancer cohorts, PTX4 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PTX4 data layer compared with 20 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PTX4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PTX4 expression acts as an unfavorable survival marker.

HNSC, BLCA, and LUSC are the cancer types where PTX4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	III,IV	0.098	0.746	<.001	27	view →
BLCA	OS	Median	All	0.149	0.687	.005	18	view →
LUSC	OS	Median	II,III,IV	0.181	0.732	.009	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

PTX4–HNSC (OS)

Open the HNSC breakdown →